|
Aug-11-26 07:15AM
|
Tenax Therapeutics stock crashes on Phase III trial failure
|
link
|
(Clinical Trials Arena)
|
|
Aug-10-26 11:03AM
|
Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103
|
link
|
(InvestorsHub)
|
|
Aug-10-26 10:52AM
|
Tenax, Sionna Shares Sink After Trial Failures
|
link
|
(The Wall Street Journal)
|
|
Aug-10-26 10:23AM
|
Why Did TENX Stock Crash 89% Today?
|
link
|
(Stocktwits)
|
|
Aug-10-26 08:25AM
|
Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout
|
link
|
(Investing.com)
|
|
Aug-10-26 07:00AM
|
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
|
link
|
(GlobeNewswire)
|
|
Jul-31-26 07:08AM
|
Tenax Therapeutics: Q2 Earnings Snapshot
|
link
|
(Associated Press)
|
|
Jul-31-26 07:00AM
|
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
|
link
|
(GlobeNewswire)
|
|
Jul-02-26 04:05PM
|
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
link
|
(GlobeNewswire)
|
|
Jul-02-26 08:48AM
|
Three Years of War Changed What Governments Buy. One Player is Already Winning Contracts (NASDAQ: MDWD)
|
link
|
(FinanceWire)
|
|
Jul-02-26 07:00AM
|
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
|
link
|
(GlobeNewswire)
|
|
May-12-26 07:07AM
|
Tenax Therapeutics: Q1 Earnings Snapshot
|
link
|
(Associated Press)
|
|
May-12-26 07:00AM
|
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
|
link
|
(GlobeNewswire)
|
|
May-08-26 04:05PM
|
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
link
|
(GlobeNewswire)
|
|
May-04-26 07:00AM
|
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
|
link
|
(GlobeNewswire)
|
|
Apr-22-26 07:00AM
|
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
|
link
|
(GlobeNewswire)
|
|
Mar-17-26 09:33AM
|
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
|
link
|
(The Fly)
|
|
Mar-10-26 07:24AM
|
Tenax Therapeutics: Q4 Earnings Snapshot
|
link
|
(Associated Press Finance)
|
|
Mar-10-26 07:00AM
|
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
|
link
|
(GlobeNewswire)
|
|
Mar-03-26 07:00AM
|
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
|
link
|
(GlobeNewswire)
|
|
Feb-15-26 01:03PM
|
Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference
|
link
|
(MarketBeat)
|
|
Feb-04-26 07:00AM
|
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
|
link
|
(GlobeNewswire)
|
|
Jan-08-26 02:00PM
|
Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick
|
link
|
(Insider Monkey)
|
|
Dec-17-25 09:16AM
|
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
|
link
|
(GlobeNewswire)
|
|
Nov-25-25 07:00AM
|
Tenax Therapeutics to Participate in Upcoming Investor Conferences
|
link
|
(GlobeNewswire)
|
|
Nov-12-25 04:17PM
|
Tenax Therapeutics: Q3 Earnings Snapshot
|
link
|
(Associated Press Finance)
|
|
Nov-12-25 04:05PM
|
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
|
link
|
(GlobeNewswire)
|
|
Nov-06-25 07:00AM
|
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
|
link
|
(GlobeNewswire)
|
|
Nov-03-25 07:00AM
|
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
|
link
|
(GlobeNewswire)
|
|
Sep-16-25 07:00AM
|
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
|
link
|
(GlobeNewswire)
|
|
Aug-28-25 07:00AM
|
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
|
link
|
(GlobeNewswire)
|
|
Aug-13-25 04:17PM
|
Tenax Therapeutics: Q2 Earnings Snapshot
|
link
|
(Associated Press Finance)
|
|
Aug-13-25 04:05PM
|
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
|
link
|
(GlobeNewswire)
|
|
May-14-25 04:38PM
|
Tenax Therapeutics: Q1 Earnings Snapshot
|
link
|
(Associated Press Finance)
|
|
May-14-25 04:05PM
|
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
|
link
|
(GlobeNewswire)
|
|
Apr-16-25 04:29PM
|
Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts
|
link
|
(Seeking Alpha)
|
|
Mar-31-25 08:00AM
|
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
|
link
|
(GlobeNewswire)
|
|
Mar-25-25 04:25PM
|
Tenax Therapeutics: Q4 Earnings Snapshot
|
link
|
(Associated Press Finance)
|
|
Mar-25-25 04:05PM
|
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
|
link
|
(GlobeNewswire)
|
|
Mar-05-25 08:47AM
|
Tenax Therapeutics Announces $25 Million Private Placement
|
link
|
(GlobeNewswire)
|
|
Mar-05-25 08:42AM
|
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
|
link
|
(GlobeNewswire)
|
|
Mar-03-25 08:00AM
|
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference
|
link
|
(GlobeNewswire)
|
|
Jan-31-25 09:00AM
|
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
|
link
|
(GlobeNewswire)
|
|
Jan-22-25 08:00AM
|
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations
|
link
|
(GlobeNewswire)
|
|
Nov-13-24 07:19AM
|
Tenax Therapeutics: Q3 Earnings Snapshot
|
link
|
(Associated Press Finance)
|
|
Nov-13-24 07:00AM
|
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
|
link
|
(GlobeNewswire)
|
|
Nov-04-24 07:30AM
|
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
|
link
|
(PR Newswire)
|
|
Oct-31-24 04:05PM
|
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
|
link
|
(GlobeNewswire)
|
|
Aug-13-24 04:37PM
|
Tenax Therapeutics: Q2 Earnings Snapshot
|
link
|
(Associated Press Finance)
|
|
Aug-13-24 04:05PM
|
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
|
link
|
(GlobeNewswire)
|
|
Aug-12-24 08:00AM
|
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
|
link
|
(GlobeNewswire)
|
|
Aug-06-24 07:13AM
|
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
|
link
|
(GlobeNewswire)
|
|
May-14-24 01:53PM
|
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q1 2024
|
link
|
(InvestorPlace)
|
|
May-14-24 08:10AM
|
Tenax Therapeutics: Q1 Earnings Snapshot
|
link
|
(Associated Press Finance)
|
|
May-14-24 08:00AM
|
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
|
link
|
(GlobeNewswire)
|
|
Apr-30-24 07:30AM
|
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
|
link
|
(GlobeNewswire)
|
|
Apr-09-24 08:30AM
|
Tenax Therapeutics to Host KOL Event: LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study
|
link
|
(GlobeNewswire)
|
|
Mar-28-24 09:54PM
|
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023
|
link
|
(InvestorPlace)
|
|
Mar-28-24 08:30AM
|
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
|
link
|
(GlobeNewswire)
|
|
Mar-12-24 08:30AM
|
Tenax Therapeutics to Present at the 36th Annual Roth Conference
|
link
|
(GlobeNewswire)
|
|
Feb-29-24 09:00AM
|
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
|
link
|
(GlobeNewswire)
|
|
Feb-20-24 08:30AM
|
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
|
link
|
(GlobeNewswire)
|
|
Feb-08-24 08:53AM
|
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?
|
link
|
(InvestorPlace)
|
|
Feb-08-24 08:16AM
|
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
|
link
|
(GlobeNewswire)
|
|
Feb-07-24 08:01PM
|
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
|
link
|
(GlobeNewswire)
|
|
Feb-06-24 08:30AM
|
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
|
link
|
(GlobeNewswire)
|
|
Dec-29-23 08:30AM
|
Tenax Therapeutics Announces Reverse Stock Split
|
link
|
(GlobeNewswire)
|
|
Nov-17-23 08:30AM
|
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board
|
link
|
(GlobeNewswire)
|
|
Nov-14-23 05:05AM
|
Tenax Therapeutics: Q3 Earnings Snapshot
|
link
|
(Associated Press Finance)
|
|
Nov-13-23 03:22PM
|
Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?
|
link
|
(InvestorPlace)
|
|
Nov-13-23 08:30AM
|
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023
|
link
|
(GlobeNewswire)
|
|
Aug-28-23 08:20AM
|
TENX: Second Quarter Results
|
link
|
(Zacks)
|
|
Aug-25-23 07:20AM
|
7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole
|
link
|
(InvestorPlace)
|
|
Jul-19-23 08:30AM
|
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
|
link
|
(GlobeNewswire)
|
|
Jun-23-23 06:24AM
|
TENX: Notice of Allowance Increases Confidence
|
link
|
(Zacks Small Cap Research)
|
|
May-31-23 08:54AM
|
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
|
link
|
(GlobeNewswire)
|
|
May-22-23 06:44AM
|
TENX: Prioritizing Levosimendan
|
link
|
(Zacks Small Cap Research)
|
|
Apr-21-23 03:59PM
|
10 Stocks Targeted By Short Sellers Recently
|
link
|
(Insider Monkey)
|
|
Apr-12-23 02:50PM
|
Tenax Therapeutics Prioritizes Development Of TNX-103 For Heart Failure
|
link
|
(Benzinga)
|
|
Apr-12-23 08:45AM
|
Tenax Therapeutics Provides 2023 Business Update
|
link
|
(GlobeNewswire)
|
|
Apr-05-23 05:49AM
|
TENX: Patents Guide the Way
|
link
|
(Zacks Small Cap Research)
|
|
Mar-22-23 08:45AM
|
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
|
link
|
(GlobeNewswire)
|
|
Feb-17-23 07:05AM
|
Analysts Are Optimistic We'll See A Profit From Tenax Therapeutics, Inc. (NASDAQ:TENX)
|
link
|
(Simply Wall St.)
|
|
Feb-15-23 08:05AM
|
TENX: New Funding Puts Wind in the Sails
|
link
|
(Zacks Small Cap Research)
|
|
Feb-07-23 12:10PM
|
Triangle pharma raising millions amid uncertain future
|
link
|
(American City Business Journals)
|
|
Feb-03-23 08:19AM
|
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
|
link
|
(GlobeNewswire)
|
|
Feb-02-23 10:43AM
|
Why Tenax Therapeutics Shares Are Gaining Today?
|
link
|
(Benzinga)
|
|
Feb-01-23 04:31PM
|
Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
|
link
|
(GlobeNewswire)
|
|
Jan-04-23 08:00AM
|
Tenax Therapeutics Announces Reverse Stock Split
|
link
|
(GlobeNewswire)
|
|
Nov-03-22 07:16AM
|
TENX: Agility Required to Unlock Considerable Upside
|
link
|
(Zacks Small Cap Research)
|
|
Oct-10-22 08:30AM
|
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
|
link
|
(GlobeNewswire)
|
|
Sep-15-22 09:29AM
|
Tenax Therapeutics Stock Jumps On Strategic Alternative Review
|
link
|
(Benzinga)
|
|
Sep-15-22 08:30AM
|
Tenax Therapeutics Announces the Evaluation of Strategic Alternatives
|
link
|
(GlobeNewswire)
|
|
Aug-28-22 09:23AM
|
Loss-Making Tenax Therapeutics, Inc. (NASDAQ:TENX) Expected To Breakeven In The Medium-Term
|
link
|
(Simply Wall St.)
|
|
Aug-23-22 05:58AM
|
TENX: The Pressures On: Awaiting Phase 3 Start
|
link
|
(Zacks Small Cap Research)
|
|
Jul-01-22 07:52AM
|
Chapel Hill company given extension to regain Nasdaq compliance
|
link
|
(American City Business Journals)
|
|
May-25-22 08:30AM
|
Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)
|
link
|
(Business Wire)
|
|
May-23-22 08:30AM
|
Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension
|
link
|
(Business Wire)
|
|
May-19-22 08:18AM
|
TENX: 1Q:22 Financial and Operational Review
|
link
|
(Zacks Small Cap Research)
|
|
May-18-22 08:30AM
|
Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
|
link
|
(Business Wire)
|
ED-Finanzas